/AFMD

AFMD Stock - Affimed N.V.

Q: What is the analyst price target for AFMD?

Analyst price target information is not currently available for AFMD.

Q: What is AFMD's market cap?

Market capitalization information is not currently available for AFMD.

Healthcare|Biotechnology|NASDAQ

$0.18+0.00%

+$0.00 (+0.00%) • Nov 25

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+4032.2%upside

Target: $7.50

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for AFMD

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta2.07

52W High$8.95

52W Low$0.02

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	$8.28M	$41.35M	$40.37M	$28.36M	$21.39M
Gross Profit	$8.28M	$41.35M	$40.37M	$28.36M	$21.39M
Gross Margin	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income	$-106,661,000	$-88,119,000	$-64,030,000	$-34,718,000	$-32,376,000
Net Income	$-105,938,000	$-86,004,000	$-57,523,000	$-41,366,000	$-32,365,000
Net Margin	-1280.2%	-208.0%	-142.5%	-145.9%	-151.3%
EPS	$-7.09	$-6.04	$-4.81	$-4.96	$-5.04

Company Overview

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

33%

Hold / Neutral

67%

Sell / Underperform

Analyst Consensus🔴 Bearish

1 Bullish2 Neutral/Bearish

Price Targets

Average Target

↑ 2103.9% Upside

Now

Low

Average

High

Based on 2 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
May 14th 2025	H.C. Wainwright	Downgrade	Neutral	-
May 13th 2025	Leerink Partners	Downgrade	Market Perform	-
December 12th 2022	H.C. Wainwright	Initiation	Buy	$6
October 10th 2022	Stifel	Downgrade	Hold	$2← $9
August 18th 2022	Wells Fargo	Resumed	Overweight	-

Earnings History & Surprises

AFMD

Beat Rate

50%

Last 18 quarters

Avg Surprise

-15.7%

EPS vs Estimate

Beats / Misses

9/8

1 met exactly

Latest EPS

$-1.38

Q2 2025

EPS Surprise History

Q4 23

+19.0%

$-1.70vs$-2.10

Q1 24

+12.3%

$-1.35vs$-1.54

Q2 24

+20.2%

$-1.38vs$-1.73

Q3 24

-9.0%

$-1.09vs$-1.00

Q4 24

+9.6%

$-1.03vs$-1.14

Q1 25

+4.4%

$-0.87vs$-0.91

Q2 25

-0.5%

$-0.87vs$-0.86

Q2 25

-165.4%

$-1.38vs$-0.52

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Nov 12, 2025	—	—	—	—
Q2 2025	Jun 11, 2025	$-0.52	$-1.38	-165.4%	✗ MISS
Q2 2025	May 28, 2025	$-0.86	$-0.87	-0.5%	✗ MISS
Q1 2025	Mar 27, 2025	$-0.91	$-0.87	+4.4%	✓ BEAT
Q4 2024	Nov 14, 2024	$-1.14	$-1.03	+9.6%	✓ BEAT
Q3 2024	Sep 5, 2024	$-1.00	$-1.09	-9.0%	✗ MISS
Q2 2024	Jun 12, 2024	$-1.73	$-1.38	+20.2%	✓ BEAT
Q1 2024	Mar 28, 2024	$-1.54	$-1.35	+12.3%	✓ BEAT
Q4 2023	Nov 14, 2023	$-2.10	$-1.70	+19.0%	✓ BEAT
Q3 2023	Aug 10, 2023	$-2.20	$-2.20	0.0%	= MET
Q2 2023	May 23, 2023	$-2.20	$-2.30	-4.5%	✗ MISS
Q1 2023	Mar 23, 2023	$-1.90	$-2.20	-15.8%	✗ MISS
Q4 2022	Nov 15, 2022	$-1.90	$-1.10	+42.1%	✓ BEAT
Q3 2022	Aug 11, 2022	$-1.80	$-1.40	+22.2%	✓ BEAT
Q2 2022	Jun 1, 2022	$-1.80	$-1.60	+11.1%	✓ BEAT
Q1 2022	Mar 31, 2022	$-1.70	$-2.20	-29.4%	✗ MISS
Q4 2021	Nov 10, 2021	$-1.30	$-1.70	-30.8%	✗ MISS
Q3 2021	Jul 1, 2021	$-0.80	$0.10	+112.5%	✓ BEAT
Q2 2021	Apr 15, 2021	$-0.53	$-2.00	-280.0%	✗ MISS
Q1 2021	Mar 31, 2021	—	$0.14	—	—